Dirk Jochmans

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Novel HIV-1 reverse transcriptase inhibitors
    Dirk Jochmans
    Tibotec BVBA, Gen De Wittelaan L 11B 3, 2800 Mechelen, Belgium
    Virus Res 134:171-85. 2008
  2. ncbi Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action
    Dirk Jochmans
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, 2800 Mechelen, Belgium
    J Virol 80:12283-92. 2006
  3. ncbi Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors
    Olivia Goethals
    Tibotec BVBA, Mechelen, Belgium
    J Virol 82:10366-74. 2008
  4. ncbi TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments
    Johan Vingerhoets
    Tibotec, Mechelen, Belgium
    J Virol 79:12773-82. 2005
  5. ncbi TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
    Sandra De Meyer
    Tibotec, Gen De Wittelaan L 11B 3, B2800 Mechelen, Belgium
    Antimicrob Agents Chemother 49:2314-21. 2005
  6. ncbi Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent
    Roger G Ptak
    Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 52:1302-17. 2008
  7. ncbi MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells
    Els Pattyn
    Department of Medical Protein Research, VIB, A Baertsoenkaai 3, 9000 Ghent, Belgium
    J Virol Methods 153:7-15. 2008

Collaborators

Detail Information

Publications7

  1. ncbi Novel HIV-1 reverse transcriptase inhibitors
    Dirk Jochmans
    Tibotec BVBA, Gen De Wittelaan L 11B 3, 2800 Mechelen, Belgium
    Virus Res 134:171-85. 2008
    ..This promising research provides much optimism that RT inhibitors will continue to evolve with subsequent clinical benefit...
  2. ncbi Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action
    Dirk Jochmans
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, 2800 Mechelen, Belgium
    J Virol 80:12283-92. 2006
    ..In conclusion, this class of indolopyridones can occupy the nucleotide binding site of HIV RT by forming a stable ternary complex whose stability is mainly dependent on the nature of the primer 3' end...
  3. ncbi Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors
    Olivia Goethals
    Tibotec BVBA, Mechelen, Belgium
    J Virol 82:10366-74. 2008
    ..These data broaden the understanding of antiviral resistance against integrase inhibitors and may give insight facilitating the discovery of second-generation compounds...
  4. ncbi TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments
    Johan Vingerhoets
    Tibotec, Mechelen, Belgium
    J Virol 79:12773-82. 2005
    ..These results demonstrate that TMC125 has a unique profile of activity against NNRTI-resistant virus and possesses a high genetic barrier to the development of resistance in vitro...
  5. ncbi TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
    Sandra De Meyer
    Tibotec, Gen De Wittelaan L 11B 3, B2800 Mechelen, Belgium
    Antimicrob Agents Chemother 49:2314-21. 2005
    ..Combinations with ritonavir, nelfinavir, and amprenavir showed some evidence of synergy. These results suggest that TMC114 is a potential candidate for the treatment of both naive and PI-experienced patients with HIV...
  6. ncbi Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent
    Roger G Ptak
    Southern Research Institute, Frederick, Maryland 21701, USA
    Antimicrob Agents Chemother 52:1302-17. 2008
    ..Thus, Debio-025 seems to interfere with the function of CypA during the progression/completion of HIV-1 reverse transcription...
  7. ncbi MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells
    Els Pattyn
    Department of Medical Protein Research, VIB, A Baertsoenkaai 3, 9000 Ghent, Belgium
    J Virol Methods 153:7-15. 2008
    ..These results show that MAPPIT can be used as a novel screening tool for anti-HIV compounds in intact human cells...